Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$199 Mln
Revenue (TTM)
$17 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.6 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
4.5
Industry P/E
--
EV/EBITDA
-6.3
Div. Yield
0 %
Debt to Equity
0.2
Book Value
$3.4
EPS
$-1.9
Face value
--
Shares outstanding
12,845,664
CFO
$-109.07 Mln
EBITDA
$-108.68 Mln
Net Profit
$-128.80 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
MediWound - ADR
| -8.9 | -2.8 | -8.9 | 4.6 | 8.1 | -14.5 | -11.5 |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|
|
MediWound - ADR
| 3.7 | -24.6 | -18.3 | -36.2 | 19.4 | -23.6 |
|
S&P Small-Cap 600
| 4.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
MediWound - ADR
|
16.8 | 198.6 | 17.0 | -23.9 | -96.8 | -63.9 | -- | 4.5 |
| 8.5 | 466.6 | 195.3 | 21.9 | 12.7 | 8.3 | 23.1 | 1.8 | |
| 2.1 | 1.9 | 0.0 | -4.8 | -- | -93.3 | 0 | 0.2 | |
| 4.4 | 80.3 | 0.0 | -34.2 | -- | -366.3 | -- | 7.2 |
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The... company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel. Address: 42 Hayarkon Street, Yavne, Israel, 8122745 Read more
Chief Financial Officer
Ms. Hani Luxenburg
Chief Financial Officer
Ms. Hani Luxenburg
Headquarters
Yavne
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of MediWound Ltd - ADR is $16.81 (NASDAQ) as of 02-Apr-2026 18:59 EDT. MediWound Ltd - ADR has given a return of 8.07% in the last 3 years.
Since, TTM earnings of MediWound Ltd - ADR is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-9.91
|
5.43
|
|
2024
|
-6.36
|
6.17
|
|
2023
|
-13.96
|
2.97
|
|
2022
|
-4.36
|
7.83
|
|
2021
|
-0.68
|
-2.01
|
The 52-week high and low of MediWound Ltd - ADR are Rs 22.51 and Rs 14.14 as of 04-Apr-2026.
MediWound Ltd - ADR has a market capitalisation of $ 199 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in MediWound Ltd - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.61
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.